Pseudomonas aeruginosa is a major cause of chronic infections in cystic fibrosis patients. 27
INTRODUCTION 40
Pseudomonas aeruginosa is an opportunistic human pathogen that causes severe infections in 41 immune-compromised individuals and is a major cause of chronic infections in cystic fibrosis 42 patients. Equipped with a type III secretion system (T3SS), P. aeruginosa can inject effector 43 proteins directly into the host cells where they contribute to virulence of the pathogen [for 44 review see 1, 2 ]. Four different T3SS delivered effectors have been characterized (exoenzyme 45 T, Y, U and S) , but new effectors were recently identified 3 . Exoenzyme Y (ExoY) is present 46 in 89% of clinical isolates 4 , and was originally identified as an adenylate cyclase in 1998 (ref. 47 5 ) due to amino acid sequence homology with two well characterized class II adenylate 48 cyclase toxins, CyaA from Bordetella pertussis and edema factor (EF) from Bacillus 49 anthracis. Recent results revealed that substrate specificity of these enzymes expressed in 50 cell cultures is not restricted to ATP: EF and CyaA were shown to use UTP and CTP as 51 substrate 6 while ExoY was shown to promote the intracellular accumulation of several cyclic 52 nucleotides 7, 8 with a preference for cGMP and cUMP over cAMP and cCMP formation 7 . 53
The physiological effects of ExoY resulting from accumulation of these cyclic nucleotides 54 include the hyperphosphorylation of tau and the disruption of microtubules causing the 55 formation of gaps between endothelial cells and increased permeability of the endothelial 56 barrier 8, 9, 10, 11 . Most recent results showed that ExoY presence correlates with long term 57 effects on recovery after lung injury from pneumonia 12 . 58 identify the putative yeast activator that was likely to be evolutionarily conserved in human 88 cells. 89 90 Identification of actin as the main protein interacting with ExoY-TAP in S. cerevisiae 91
To identify putative ExoY-binding proteins in yeast, we expressed ExoY containing a C-92 terminal epitope-tag (ExoY-TAP or ExoY-HA) in S. cerevisiae to isolate proteins co-93 purifying with the affinity purified bait protein. To avoid toxic effects due to cyclic 94 nucleotide accumulation, we expressed a catalytically inactive variant of ExoY, ExoY K81M 95 (in which the Lys81 was changed to Met 5 ). Material obtained in a one-step purification using 96
IgGs covalently bound to magnetic beads was directly processed by tryptic digestion for 97 protein identification through LC-MS/MS. The raw data were then analyzed by MaxQuant 98 for protein identification and quantitative estimation of the specific enrichment of proteins in 99 the experimental sample (ExoY K81M -TAP) as compared to the control (ExoY K81M -HA). 100 While many abundant proteins were present in both samples to a comparable degree, as 101 estimated from the label free quantitation score (LFQ, 18 ), ExoY was identified only in the 102 purification done with ExoY K81M -TAP extract, as expected. A second protein that was about 103 1000 times more abundant in the ExoY K81M -TAP purification than in the control was yeast 104 actin (Uniprot P60010, YFL039C, Act1), which showed an LFQ score close to the score of 105 the tagged ExoY (Fig. 1b) . Other factors were identified specifically in the ExoY K81M -TAP 106 purification, but with much lower LFQ scores (see Supplementary table 2 ). These results 107 suggest a specific interaction of ExoY K81M with yeast Act1. Since actin is one of the most 108 highly conserved and abundant proteins in eukaryotic cells, it appeared to be a potential 109 candidate for activating ExoY ubiquitously in eukaryotic cells. 110 111 112
ExoY interacts with mammalian actin in vitro 113
To verify the interaction between ExoY and mammalian actin in vitro, we performed Ni-114 NTA agarose pulldowns. ExoY with a C-terminal Flag-His tag (ExoY-FH) and α-actin from 115 rabbit skeletal muscle (Cytoskeleton, Inc., designated here MA-99) were added at equimolar 116 concentrations to Ni-NTA agarose beads in batch. After 1 hr incubation the beads were 117 washed in Durapore columns and the retained proteins were eluted with imidazole. While 118 very little actin was bound unspecifically to the beads in the absence of ExoY, considerably 119 more actin was present in the eluate from the sample containing ExoY-FH, suggesting 120 specific binding between the two pure proteins ( Fig. 2a) . 121
Under our experimental conditions, which promote actin spontaneous polymerization 122 (300 mM NaCl, 2.5 μM ATP, 660 nM actin), actin should exist in solution both in its 123 monomeric (G-actin) and filamentous (F-actin) states. To investigate more specifically 124 whether ExoY could bind to F-actin, we performed high-speed co-sedimentation assays: we 125
Since in mammalian cells the transfection with a vector expressing ExoY led to accumulation 137 of cGMP to levels exceeding that of cAMP 7, 8 , we also tested GTP as substrate and found 138 that, in agreement with the preferential accumulation of cGMP over cAMP observed in vivo, 139 the guanylate cyclase activity of HF-ExoY was approximately 8 times higher than the 140 adenylate cyclase activity in the presence of actin in vitro (Fig. 3a) . The background activity 141 without actin was estimated to be about 1 nmol and 10 nmol.min -1 .mg -1 for cGMP and 142 cAMP, respectively. Thus, the ExoY nucleotidyl cyclase activity was stimulated more than 143 10,000 fold by submicromolar concentrations of F-actin. Different mammalian actin isoforms 144 (A-99, a mixture of 85% β-and 15% γ-actin, or α-actin from rabbit skeletal muscle) led to a 145 similar activity for cGMP synthesis ( Supplementary Fig. 2 ). All together these data indicate 146 that actin is a specific activator of ExoY in eukaryotic cells. Subsequent experiments were 147 performed using highly pure skeletal muscle α-actin purified in one of our laboratory 148 (designated MA-L). 149
To examine a possible dependence of ExoY activation on the different states of actin 150 (ATP-versus ADP-bound, monomeric versus polymeric forms), we measured ExoY cGMP 151 synthesis activity at different actin concentrations below or above the critical polymerizing 152 concentrations in different actin nucleotide states. Measurements were performed at various 153 concentrations of actin that was initially loaded with either Mg-ATP or Mg-ADP. A similar 154 maximal activity of 1000 -1200 μmol of cGMP.min -1 .mg -1 was obtained with both ATP-155 bound and ADP-bound actin (Fig. 3b ). In contrast, the actin concentrations required for half 156 maximal activation of ExoY (K 1/2 ) were dependent upon the bound nucleotides. The actin 157 concentration for half maximal ExoY activation with ATP-loaded actin was about 0.2 µM 158 ( Fig. 3b ). This is just above the critical concentration of 0.1 μM above which Mg-ATP-actin 159 spontaneously polymerizes in solution with salt 19 . Conversely, the actin concentrations 160 required for half-maximal ExoY activation with ADP-loaded actin was about 2.4 µM ( Fig.  161 3b), a shifted value that correlates with the alternative critical concentration of 1.7 μM 162 obtained with Mg-ADP-actin. Altogether, these results suggest that the maximal activation of 163 ExoY by actin was correlated with F-actin formation. 164 165
Activation of ExoY by actin is antagonized by latrunculin A or G-actin binding proteins 166
We then examined whether proteins or molecules that are known to bind to G-actin and to 167 inhibit its polymerization or spontaneous nucleation, could affect the activation of ExoY by 168 actin. We examined the activation of ExoY by G-actin in the presence of the drug latrunculin 169 A or G-actin binding proteins such as profilin or thymosin-β4 (Tβ4), which are among the 170 main monomeric actin-binding proteins in vertebrate cells 19 . These three molecules are 171 known to inhibit actin polymerization or spontaneous nucleation by binding to distinct G-172 actin interfaces. The small macrolide Latrunculin A from the Red Sea sponge Negombata 173 magnifica 20, 21 inhibits actin self-assembly by binding (K D ≈ 0.2 μM) to a cleft located on the 174 pointed face of G-actin. The protein profilin binds (K D ≈ 0.1 μM) in contrast to the opposite 175 face of monomers, called barbed face, and favors in vivo the unidirectional elongation of the 176 most-dynamic barbed ends of filaments. In vitro, G-actin:profilin complexes inhibit actin 177 spontaneous nucleation and thus polymerization in absence of actin nuclei or filament seeds. 178
Tβ4 is a small intrinsically disordered β-thymosin domain of 4 kDa that acts as a major G-179 actin-sequestering polypeptide in cells 22, 23 . Here, we used a chimeric β-thymosin domain 180 between Tβ4 and ciboulot from Drosophila called Chimera 2 (CH2), as it exhibits a higher 181 affinity for G-actin than Tβ4 (K D~0 .5 μM versus 2 μM) while retaining its sequestering 182 activity 22, 23 . Like Tβ4, CH2 displays an extended binding interface on actin monomers by 183 interacting with both their barbed and pointed faces 22, 23, 24 . 184 In ExoY activity measurements, actin monomers were saturated by the above 185 molecules to inhibit or significantly slow down the spontaneous nucleation or polymerization 186 of actin in solution. The inhibitory effect on actin assembly was verified in cosedimentation 187 assays ( Supplementary Fig. 3 ). In these conditions, all molecules tested inhibited ExoY 188 activation by micromolar actin concentrations ( Fig. 4) , which normally induce maximal 189 activation of the toxin. CH2 reduced at least 9 fold (up to 15) the ExoY activity measured in 190 the presence of 1-3 μM of actin ( Fig. 4 ). Latrunculin A reduced at least 7 fold (up to 13) and 191 profilin decreased at least 4 fold (up to 7) the ExoY activity at similar ranges of actin 192 concentrations ( Fig. 4 ). Latrunculin A, profilin, and CH2 did not affect the low background 193 activity of ExoY in the absence of actin. These data thus indicated that filamentous-actin is 194 the preferred activator of ExoY. 195 196 ExoY is an F-actin binding protein that can modify the intrinsic or regulated dynamics 197 of filaments by binding along filament sides 198
We next examined whether ExoY affects the intrinsic or regulated dynamics of actin self-199 assembly in vitro in assembly/disassembly assays with ExoY /ExoY K81M . The kinetics of 200 polymerization or depolymerization were monitored by following the increase or decrease, 201 respectively, in pyrene-actin fluorescence intensity (pyrenyl-labeled actin subunits exhibit 202 higher fluorescence when incorporated in filaments than free in solution). In polymerization 203 kinetics, ExoY slightly accelerated the rate of G-actin-ADP-Mg ( Fig. 5a ) and G-actin-ATP-204 Mg (Fig. 5b ) self-assembly, confirming that ExoY can interact with actin without preventing 205 its self-assembly. Yet, this stimulation of G-actin-ATP/ADP polymerization by ExoY was 206 detectable only at high ExoY concentrations (in µM range). The dose-dependent acceleration 207 was independent of the ExoY adenylate cyclase activity since it was observed with the 208 inactive ExoY K81M variant and also with the wild-type ExoY when only ADP was present. 209
We further examined whether the ExoY-stimulation of actin polymerization was achieved by 210 increasing elongation rates on barbed-or pointed-end, or by severing filaments, but found no 211 effects of the toxin on these processes ( Supplementary Fig. 4 ). We were unable to isolate 212 stable G-actin/ExoY complexes in solution even at micromolar concentrations of both 213 proteins (and in presence of latrunculin A to prevent actin polymerization). Besides, the 214 ExoY-induced stimulation of actin polymerization was fully inhibited when actin was 215 saturated by profilin ( Fig. 5b) . These results confirm that ExoY is unlikely to stimulate actin 216 polymerization in host cells. Indeed, profilin-actin complexes form the major part of the 217 polymerization competent G-actin pool within eukaryotic cells 19, 24 . 218 To delineate the interaction of ExoY with F-actin, we performed dilution-induced 219 depolymerization assays monitoring filament disassembly from free barbed-and pointed 220 ends. As shown in Fig.5c , ExoY K81M inhibited the spontaneous disassembly of F-actin 221 induced by dilution. This indicates that ExoY directly binds to filaments and thus stabilizes 222 actin inter-subunit contacts. The inhibition of filament disassembly by ExoY K81M was also 223 observed when barbed ends were capped by gelsolin ( Fig. 5c ), thus excluding the possibility 224 that ExoY inhibited disassembly by binding to barbed ends. These results and the absence of 225
ExoY effects on the pointed-end elongation rate ( Supplementary Fig. 4 ) indicate that ExoY 226 binds along the sides of filaments where it likely interacts with several adjacent actin 227 subunits thus stabilizing actin inter-subunit contacts and preventing spontaneous disassembly 228 of filaments. 229
The binding of ExoY to filamentous actin was then quantified by co-sedimentation 230 assays using F-actin steadily polymerized in the presence of ADP-BeF 3 -(that mimics the 231 filament transition state F-actin-ADP-Pi) in order to keep most actin firmly polymerized 232 despite the efficient ATP-hydrolyzing activity of ExoY. To quantify more rigorously the 233
ExoY bound to F-actin on SDS-PAGE gels in presence of high concentrations of F-actin (as 234
ExoY and actin have close molecular weights), we used an ExoY protein fused to the 235 Maltose-Binding-Protein (MBP), MBP-ExoY (note that MBP-ExoY has also a C-terminal 236 Strep-Tag). As shown in Fig. S5 , MBP-ExoY or MBP-ExoY K81M , which alone partitioned in 237 the supernatant fraction, both pelleted with F-actin in a dose-dependent manner, and were 238 almost completely found in the pellet fraction at concentrations above 25 µM F-actin-ADP-239
BeF 3 -, i.e. much below the F-actin concentrations in cells 25 . The estimated dissociation 240 constants (Kd) of MBP-ExoY or MBP-ExoY K81M for F-actin-ADP-BeF 3 -(0.8±0.3µM and 241 2.5±0.4µM, respectively) ( Supplementary Fig. 5 ), were in the same range as that of a number 242 of eukaryotic cytoskeletal proteins that bind along filaments 26, 27, 28 . 243
Finally, we analyzed whether ExoY binding to F-actin could interfere with the 244 regulation of filament dynamics by eukaryotic cytoskeletal proteins that are known to bind 245 along the sides of filaments. We considered two key regulatory proteins that are ubiquitous 246 among eukaryotic cells: Arp2/3 complex and Actin-Depolymerizing Factor (ADF). The 247
Arp2/3 complex, upon its activation by VCA domains of the WASP family proteins, can 248 attach to the side of a pre-existing filament and catalyzes actin filament branching 26, 29 . 249 ADF/cofilin proteins, present at micromolar concentrations in eukaryotic cells, bind 250 cooperatively and preferentially to F-actin-ADP subunits along filaments (Kd~0.1µM), 251 stimulating their disassembly and thus the turnover of actin filaments in cells 19, 26 . 252 We performed actin polymerization assays with G-actin saturated by profilin to 253 simulate a more physiological context 19, 24, 30 . As shown in Fig. 5d , the acceleration of actin 254 polymerization by Arp2/3 (25-35 nM), activated by N-WASP VCA domain, was 255 significantly inhibited by high concentrations (≥100 nM) of ExoY K81M . This inhibition 256 demonstrates that ExoY could antagonize the binding of the activated Arp2/3 complex along 257 filaments and hence VCA-Arp2/3 regulation. In dilution-induced F-actin-ADP disassembly 258 assays, ExoY K81M (100 nM ) were able to completely inhibit the acceleration of filament 259 disassembly promoted by ADF (4 µM ) ( Fig. 5e ). This inhibition suggests that ExoY (at 260 submolar ratio with respect to ADF) could prevent the cooperative binding of ADF along F-261 actin-ADP and its disassembling activity. 262 263
ExoY co-localizes with actin fibers in mouse NIH3T3 cells 264
To our knowledge, the localization of ExoY in eukaryotic cells was not previously reported 265 and is of particular interest in light of its direct interaction and good affinity with naked F-266 actin in vitro. To avoid potential toxic effects of ExoY when expressed in eukaryotic cells, 267
we examined the localization of the catalytically inactive variant ExoY K81M fused to AcGFP, 268 a monomeric green fluorescent protein. The ExoY K81M -AcGFP fusion protein was 269 constitutively expressed from pUM518 under the control of the P CMV IE promoter in 270 transiently transfected NIH3T3 cells. Acti-stain TM 555 fluorescent phalloidin (Cytoskeleton, 271 Inc.) was used to visualize F-actin in cells. Unlike GFP alone, which showed a homogeneous 272 cytoplasmic and partially nuclear localization, the signal for ExoY K81M -AcGFP partially co-273 localized in vivo with F-actin filaments (Fig. 6 ). 274
275
The ExoY-like virulence factor present in the Vibrio nigripulchritudo MARTX toxin is 276 also activated by actin 277
Finally we examined whether actin could also activate other putative ExoY-like cyclases 278 that can be found in various MARTX toxins that are produced by several Gram-negative 279 pathogens including Burkholderia or several Vibrio 13 , Providencia, or Proteus species 280 ( Fig. 7a ). For this, we selected the ExoY-like module from the MARTX toxin encoded by 281 the virulence-associated plasmid pA SFn1 from Vibrio nigripulchritudo 13, 31 , an emerging 282 marine pathogen infecting farmed shrimps. The multidomain MARTX toxin is processed 283 inside host cells by an inbuilt cysteine protein domain (CPD), into individual effector 284 domains 32 . The N-and C-terminus of the V. nigripulchritudo ExoY-like effector domain 285 were chosen based on sequence alignments of P. aeruginosa ExoY and ExoY-like 286 containing sequences from several Vibrio MARTX toxins ( Supplementary Fig. 6 ), the 287 signature of CPD cleavage sites present in some Vibrio ExoY-like modules and HCA 288 secondary prediction analysis. The MARTX-ExoY protein corresponding to residues 289 Y3412 to L3872 of Uniprot reference F0V1C5 was termed here VnExoY-L. The protein 290 carrying a C-terminal Flag-His tag (VnExoY-L-FH) was purified and tested for its 291 adenylate cyclase activity in the presence and absence of actin. Fig. 7b shows that 292
VnExoY-L displayed a potent adenylate cyclase activity in the presence of actin, which 293 stimulates the enzymatic activity more than 10,000 fold. In contrast to P. aeruginosa 294 ExoY, VnExoY-L did not exhibit any cGMP synthesizing activity. We conclude that actin 295 may be a common activator of the various ExoY-like cyclase modules, even though these 296 differ in their substrate selectivity. 297
298

DISCUSSION 299
Actin is the target of a variety of bacterial toxins. These toxins can affect the polymerization 300 state of actin in different ways by introducing modifications, namely ADP-ribosylation at 301 different position or crosslinking (for reviews see 33, 34 ). The provoked rearrangements have a 302 profound effect on the cytoskeleton of the host cells and affect their response to bacterial 303 invasion. 304
Here, we show that actin is a potent activator of a group of bacterial toxins that are 305 homologous to the P. aeruginosa ExoY effector and that display nucleotidyl cyclase 306 activities with different substrate selectivity. 307
We identified actin as a potential candidate for P. aeruginosa ExoY activation 308 through its enriched presence among the proteins that co-purified with TAP-tagged ExoY 309 expressed in S. cerevisiae. Actin is among the most abundant proteins in eukaryotic cells 310 with a large number of known interaction partners. It is also frequently retrieved un-311 specifically in "pull-down" experiments and it is ranked among the top contaminants in the 312 so-called "CRAPome", Contaminant Repository for Affinity Purification 35 . In our case, 313 however, we found that the interaction between ExoY and actin is highly specific and 314 conserved between yeast and different mammalian actin isoforms. We further showed that 315
ExoY is an F-actin binding protein (Fig. 5 ) and we demonstrated that F-actin is a potent 316 activator of ExoY, able to stimulate its adenylate and guanylate cyclase activity more than 317 10,000 fold. In accordance with this view, we found that ExoY activation by actin was 318 strongly antagonized by different G-actin binding proteins, such as profilin, or a Tβ4-319 derivative protein with similar activity as Tβ4 (CH2), or by latrunculin A that prevents actin 320 polymerization (Fig. 4) . Profilin and latrunculin A interact with non-overlapping, opposite 321 binding sites on G-actin, which are mostly buried by actin:actin contacts in filaments. 322
Profilin may partially overlap and compete with ExoY binding sites as it inhibits as well 323
ExoY-mediated stimulation of actin self-assembly (Fig. 5b) . In contrast, the antagonizing 324 effect of the small molecule latrunculin A is likely due to its inhibition of actin 325 polymerization rather than to a steric hindrance of the ExoY binding-sites. In the presence of 326 saturating concentrations (> 2-5 μM) of F-actin, the very low basal enzymatic activity of 327
ExoY was strongly stimulated to reach specific activities of about 120 μmol.min -1 .mg -1 and 328 900 μmol.min -1 .mg -1 for cAMP and cGMP synthesis, respectively. The higher guanylate 329 cyclase activity as compared to the adenylate cyclase one is in agreement with the 330 preferential accumulation of cGMP over cAMP observed in vivo 7, 8 . The corresponding kcat 331 for cGMP synthesis is approaching 1000 s -1 and therefore within the same order of 332 magnitude as the catalytic rates measured for cAMP synthesis for the related cyclase toxins 333
CyaA or EF, when activated by calmodulin, their common eukaryotic activator 36, 37 . 334 While ExoY represents to our knowledge the first example of a bacterial toxin that is 335 activated by F-actin, G-actin has been shown before to activate a bacterial toxin secreted by 336 the T3SS namely YopO/YpkA, a multidomain protein produced by pathogenic Yersinia Supplementary Fig. 5 ) that should allow efficient competition in vivo with many 347 eukaryotic cytoskeletal side-binding proteins that also bind along filaments with sub-to low 348 micromolar affinities 26, 27, 28 . In agreement with this, we found that, in vitro, ExoY could 349 antagonize the regulation of actin self-assembly dynamics by VCA-activated Arp2/3 350 complex ( Fig. 5d ) and/or the Actin-Depolymerizing Factor (ADF) (Fig. 5e ExoY-GFP with actin filaments in transfected NIH3T3 cells (Fig. 6 ). As many F-actin 357 binding proteins, ExoY can also weakly interact with actin monomers as indicated by the fact 358 that (i) ExoY is weakly activated (up to 5-10 % of maximal activity) in a dose dependent 359 manner by actin bound to the polymerization-inhibiting drug latrunculin A (Figs. 3b and 4) 360 and that (ii) ExoY weakly stimulated G-actin-ATP/-ADP polymerization in absence of 361 profilin (Fig. 5a,b) . 362
While most of the ExoY related effects in infected cells likely depend on its catalytic 363 activity, the catalytically inactive ExoY K81M mutant has been observed to induce temporary 364 actin redistribution to the cell margins 10 as well as minimal intercellular gap formation 11 in 365 endothelial cells. These effects may be linked to a residual nucleotide cyclase activity of 366 ExoY K81M and/or to its direct binding to actin polymers in host cells. We showed that in vitro 367 Providencia, Burkholderia or Proteus (Fig. 7a ). Here we showed that VnExoY-L, a rather 381 distantly related ExoY-like module from V. nigripulchritudo (38% sequence similarity with 382 P. aeruginosa ExoY and 28% with B. anthracis EF or B. pertussis CyaA, Fig. 7a and 383 Supplementary Table 3 ), was also strongly stimulated (over a 10,000 fold) by actin and 384 efficiently synthesized cAMP but not cGMP. The lack of guanylate cyclase activity is in 385 agreement with the results obtained with the V. vulnificus ExoY-like module 13 , a close 386 homolog of VnExoY-L (>75% sequence similarity, Fig. 7a and Supplementary Table 3 ), and 387 may thus reflect a more general difference regarding the nucleotide substrate specificities 388 between the P. aeruginosa ExoY and other ExoY-like proteins found in MARTX toxins like 389 those of the Vibrio genus ( Fig. 7a and Supplementary Fig. 6 ). 390
Actin may thus represent a common eukaryotic activator for a sub-group (Fig. 7a ) of 391 the class II adenylyl cyclase toxin family (described in 16 ). This newly defined, actin-392 activated nucleotidyl cyclase (AA-NC) sub-family is also characterized by wider nucleotide 393 substrate specificity than the original class II members, the adenylate cyclase toxins CyaA 394 from B. pertussis and EF from B. anthracis. As calmodulin, the common cofactor of CyaA 395 and EF, actin is an abundant and highly conserved protein specific to eukaryotic cells. It 396 appears, therefore, to be a suitable molecular signal to indicate the arrival of the ExoY toxin 397 in the eukaryotic environment of the host target cells, where it should display its cyclic 398 nucleotide synthesizing activity. 399
Future studies should address the mechanism of activation of ExoY and ExoY-like 400 proteins by actin through structural analysis. This could eventually open several interesting 401 prospects in particular regarding the development of small molecules able to specifically 402 inhibit the activation of these toxins by actin, as a therapeutic approach against bacterial 403 infections, as well as the structural basis of the differential substrate selectivity of these AA-404
NCs. 405
Interestingly, Beckert et al. 7 have reported notable differences in accumulation of 406 various cNMPs in different cell lines exposed to P. aeruginosa ExoY, in particular, with 407 respect to the mode of delivery of the toxin (transfection versus infection). It will be 408 interesting to examine whether the relative efficacy in synthesizing different cNMPs depends 409 solely on availability of substrates or whether the actin dynamics and turnover in cells may 410 also play a role. 411 412 413
MATERIAL AND METHODS 414
Strains, plasmids and growth conditions 415
Strains, plasmids and growth conditions are described in table S1. free protease inhibitor cocktail (Roche)] were allowed to bind in batch to 5 μl Ni-NTA 480 agarose (Quiagen) for 1 h at 4 °C rotating in Durapore filter units (Millipore). Unbound 481 material was removed by centrifugation at 1,000 g for 1 min, after which the beads were 482 washed three times with 450 μl of binding buffer and once with binding buffer supplemented 483 with 40 mM imidazole. Elution of bound proteins was performed by adding 50 µl of binding 484 buffer supplemented with 0.5 M imidazole followed by incubation on ice for 10 min after 485 which the eluate was collected by centrifugation at 3,000 g for 1 min. A second elution was 486 carried out using 20 μl of elution buffer. A 12 μl aliquot of the combined eluates was 487 analyzed by SDS-PAGE. 488 F-actin co-sedimentation assays (Fig. 2b) Under the conditions used, reactions were time linear for at least 20 minutes. Reactions 530 were stopped by the addition of 450 μl stop solution (20 mM HEPES pH 7.5, 20 mM 531 EDTA, 0.5 mM cAMP) and the mixtures were filtered on Al 2 O 3 columns, which included 532 3 washes with 1 ml 20 mM HEPES pH 7.5 each to separate nucleotide substrates that were 533 retained in the columns from cyclic nucleotides present in the filtrates. Filtrates were 534 collected in 20 ml scintillation vials. 16 ml scintillation liquid (HiSafe3, Perkin Elmer) 535 were added before measuring 33 P in a TriCarb scintillation counter (Perkin Elmer). All 536 reactions were performed in duplicates. Differences between cpm values of most 537 duplicates were around or less than 10%. Standard deviations between duplicates are 538 indicated by error bars. 539
Muscle actin 99% pure (designated MA-99) from rabbit skeletal muscle 540 (Reference AKL99), or 99% pure non-muscle actin from human platelets (Reference 541 APHL99, designated A-99) was obtained from Cytoskeleton, Inc. Alternatively, we used 542 actin from rabbit skeletal muscle prepared in one of our laboratories (designated MA-L) 543 according to the procedure described above. For activity assays, all actin solutions were 544 diluted in G-buffer supplemented with BSA at 0.1 mg/ml. 545
Preliminary experiments to optimize reaction conditions showed that ExoY-FH 546 was most active at pH values between 8 and 9 and in Tris as compared to HEPES or Na-547 phosphate and shows a broad optimal NaCl concentration (between 100 and 300 mM 548 NaCl). 549
Extracts from HeLa cells for activation of ExoY were prepared as follows: Cells 550 grown in Dulbecco's modified Eagle's medium (DMEM) + 10% fetal bovine serum were 551 harvested after reaching 75% of confluence as follows: One wash with PBS was followed 552 by incubation in 10 ml PBS containing 0.01M EDTA for 5 min at 37 ºC before detaching 553 the cells by gentle tapping of the flasks. Cells were collected by centrifugation and washed 554 3 times in PBS. The cell pellet was resuspended in 2 ml of lysis buffer [50 ml Tris pH 7.5, 555 300 mM NaCl, 0.5 % NP50, complete EDTA-free protease inhibitor cocktail (Roche)] per 556 ml of cell pellet volume, after which the cells were snap frozen in liquid nitrogen and 557 stored at -80 ºC or processed immediately. Frozen cells were allowed to thaw on ice, 558 rotated at 4 ºC for 20 min and centrifuged for 1 h at 18,000 rpm in a SS34 rotor (Sorval). 559
The supernatant was centrifuged at 100,000 rpm at 4 ºC for 1 h in a TLA-110 rotor 560 (Beckmann). The resulting supernatant was filtered through a 0.45 μM durapore PVDF 561 filter unit (Millipore) and dialyzed against Tris/Triton/Glycerol buffer (TTG-buffer) 562 containing 25 mM Tris pH 8.0, 0.1 % Triton X-100, 10 % glycerol, 1 mM DTT, 0.4 mM 563 PMSF). Insoluble material was removed by centrifugation at 18,000 rpm in a SS34 rotor 564 at 4 ºC for 20 min. HeLa cell extract prepared according to this protocol contained 565 approximately 10 mg/ml of protein and was stored in aliquots at -20 ºC. 566
Extracts from S. cerevisiae were prepared from 100 ml cultures grown in YPD to 567 an OD600 between 0.5 and 2, at which cells were harvested by centrifugation, washed 568 once with water, and resuspended in 300 μl yeast lysis buffer [50 mM Tris pH 7.4, 50 mM 569 KCl, 1 mM DTT, complete EDTA-free protease inhibitor cocktail (Roche)]. Cells were 570 subsequently vortexed for a total of 5 min (5 times 1 min to prevent overheating) at 4 ºC. 571
Debris were removed by centrifugation at 16,000 rpm for 15 min at 4 ºC. The resulting 572 extract contained about 4 mg/ml protein and was stored at -20 ºC after the addition of 573 glycerol to a final concentration of 10 %. 574
Cycles of freezing and thawing did not seem to affect the activity of the cofactor 575 necessary for ExoY activation in extracts from HeLa cells or S. cerevisiae. 576
Mg-ATP-actin was prepared from MA-L as follows: 90 μl of MA-L at 22.22 μM 577 were added to 10 μl 10 x ME buffer (420 μM MgCl 2 , 4 mM EGTA) and incubated for 10 578 min at RT and put on ice. 579 A 34 μM solution of Mg-ADP-actin was prepared as follows: Ca-ATP-actin (MA-580 L) was converted to Mg-ATP-actin by adding 100x concentrated ME-buffer and 581 incubating for 10 min at RT to achieve a final concentration of 40 μM MgCl 2 and 0.2 mM 582 EDTA. 15 U/ml of Hexokinase (Roche) was added together with glucose to a 583 concentration of 5 mM followed by 30 min incubation on ice. ApppppA was then added to 584 10 μM and the mixture was incubated for 5 min on ice. ADP and TCEP was added to 0. ExoY. Reactions containing actin (+/-inhibitor) and ExoY-FH were preincubated for 10 min 893 at 30 ºC and started by the addition of 2 mM GTP and continued for 10 min. Latrunculin A: 894 latrunculin A (at a final concentration of 10 μM) was added to actin and preincubated for 10 895 min at room temperature before conversion to Mg-ATP-actin and processing as for the 896 control. Profilin: Profilin was added to Ca-ATP-G-actin at a 2:1 ratio. Control reactions 897 lacking latrunculin or profilin contained G-actin (MA-L) that was converted to Mg-ATP-G-898 actin and allowed to polymerize to steady state conditions before dilution to the indicated 899 concentrations. Chimera 2 (CH2) for a final concentration of 5 μM was added to muscle G- 
